BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancrea
BioSante Pharmaceuticals, Inc. today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer.